Evidence map›Paper›PMID 42474358›Full record

ArticleCancer biology & therapy2026

Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin.

Jolanta Kryczka, Jakub Mateusz Kryczka, Łukasz Janczewski, Sho Shimida, Andrzej Frączyk, Beata Kolesińska, Joanna Boncela, Ewa Brzeziańska-Lasota

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jolanta KryczkaDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.ORCID 0000-0002-7342-7342
Jakub Mateusz KryczkaLaboratory of Cell Signalling, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.ORCID 0000-0002-5719-4139
Łukasz JanczewskiInstitute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Lodz, Poland.ORCID 0000-0003-4689-1622
Sho ShimidaFaculty of Science and Technology, Keio University - Keio Gijuku Daigaku, Kohoku, Yokohama, Japan.ORCID 0009-0000-2718-2252
Andrzej FrączykInstitute of Applied Computer Science, Lodz University of Technology, Lodz, Poland.ORCID 0000-0001-8847-1808
Beata KolesińskaInstitute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Lodz, Poland.ORCID 0000-0002-4581-947X
Joanna BoncelaLaboratory of Cell Signalling, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.ORCID 0000-0001-8419-7012
Ewa Brzeziańska-LasotaDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.ORCID 0000-0002-0882-1458

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer presents complex etiopathology involving a mix of genetic predispositions and environmental factors. The best treatment modality is surgical resection. However, it becomes ineffective in the advanced metastatic stage. Thus, cisplatin-based chemotherapy, though restricted by an intrinsic and/or acquired chemo-resistant phenotype, remains the first-line therapy for advanced non-small-cell cancer (NSCLC).

methodsVarious tools were used to verify the mRNA expression and protein levels of ABC and ALDH proteins in patient-derived non-small-cell lung cancer (NSCLC) samples (GSE102287, GSE43580) and cell lines A549 and NCI-H158 (including their respective cisplatin-resistant variants) to verify the cisplatin-sensitizing abilities of newly synthesized bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide-non-toxic ALDH and ABCC2 inhibitors.

resultsWe identified significant molecular differences in the expression levels of ABCC1, ABCC5, ABCC3, ALDH7A1, and ALDH3A1. Additionally, a fairly significant patient subgroup (Z-score > 1.5), characterized by ABCC2 and ALDH3A1 overexpression, was identified. Importantly,

conclusionsMolecular categorization of NSCLC cancer is essential for predicting therapy outcomes, enabling the use of bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide as a cisplatin therapy enhancer for NSCLC patients' subpopulation with significant ABCC2 and ALDH3A1 overexpression.

Indexed as

Aldehyde DehydrogenaseATP-Binding Cassette, Sub-Family C ProteinsCarcinoma, Non-Small-Cell LungCisplatinDisulfidesLung NeoplasmsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMultidrug Resistance-Associated Protein 2ABCC2 protein, humanAldehyde DehydrogenaseALDH3A1 protein, humanAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCisplatinDisulfidesMultidrug Resistance-Associated Protein 2ABCALDHchemo-resistancecisplatincisplatin-resistanceNon-small cell lung cancerNSCLC

Identifiers

PMID42474358
PMCPMC13387110

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.